These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

452 related articles for article (PubMed ID: 35073913)

  • 1. HbA1c variability predicts cardiovascular complications in type 2 diabetes regardless of being at glycemic target.
    Ceriello A; Lucisano G; Prattichizzo F; La Grotta R; Franzén S; Svensson AM; Eliasson B; Nicolucci A
    Cardiovasc Diabetol; 2022 Jan; 21(1):13. PubMed ID: 35073913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Baseline Glycemic Control on Residual Cardiovascular Risk in Patients With Diabetes Mellitus and High-Risk Vascular Disease Treated With Statin Therapy.
    Menon V; Kumar A; Patel DR; John JS; Wolski KE; McErlean E; Riesmeyer JS; Weerakkody G; Ruotolo G; Cremer PC; Nicholls SJ; Lincoff AM; Nissen SE
    J Am Heart Assoc; 2020 Jan; 9(1):e014328. PubMed ID: 31852422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Empagliflozin reduced long-term HbA1c variability and cardiovascular death: insights from the EMPA-REG OUTCOME trial.
    Ceriello A; Ofstad AP; Zwiener I; Kaspers S; George J; Nicolucci A
    Cardiovasc Diabetol; 2020 Oct; 19(1):176. PubMed ID: 33050931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased risk of cardiovascular mortality by strict glycemic control (pre-procedural HbA1c < 6.5%) in Japanese medically-treated diabetic patients following percutaneous coronary intervention: a 10-year follow-up study.
    Funamizu T; Iwata H; Nishida Y; Miyosawa K; Doi S; Chikata Y; Shitara J; Endo H; Wada H; Naito R; Ogita M; Dohi T; Kasai T; Okazaki S; Isoda K; Miyauchi K; Daida H
    Cardiovasc Diabetol; 2020 Feb; 19(1):21. PubMed ID: 32070335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term visit-to-visit glycemic variability as predictor of micro- and macrovascular complications in patients with type 2 diabetes: The Rio de Janeiro Type 2 Diabetes Cohort Study.
    Cardoso CRL; Leite NC; Moram CBM; Salles GF
    Cardiovasc Diabetol; 2018 Feb; 17(1):33. PubMed ID: 29477146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Associations of HbA1c and educational level with risk of cardiovascular events in 32,871 drug-treated patients with Type 2 diabetes: a cohort study in primary care.
    Östgren CJ; Sundström J; Svennblad B; Lohm L; Nilsson PM; Johansson G
    Diabet Med; 2013 May; 30(5):e170-7. PubMed ID: 23350893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improvement of glycemic control in type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.
    Monami M; Candido R; Pintaudi B; Targher G; Mannucci E;
    Nutr Metab Cardiovasc Dis; 2021 Aug; 31(9):2539-2546. PubMed ID: 34158243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Associations of Glycemic Control With Cardiovascular Outcomes Among US Hemodialysis Patients With Diabetes Mellitus.
    Rhee JJ; Zheng Y; Montez-Rath ME; Chang TI; Winkelmayer WC
    J Am Heart Assoc; 2017 Jun; 6(6):. PubMed ID: 28592463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes.
    Paul SK; Klein K; Thorsted BL; Wolden ML; Khunti K
    Cardiovasc Diabetol; 2015 Aug; 14():100. PubMed ID: 26249018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic Significance of Long-term HbA
    Sheng CS; Tian J; Miao Y; Cheng Y; Yang Y; Reaven PD; Bloomgarden ZT; Ning G
    Diabetes Care; 2020 Jun; 43(6):1185-1190. PubMed ID: 32229597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peripheral arterial disease and type 2 diabetes: Older patients still exhibit a survival benefit from glucose control.
    Höbaus C; Herz CT; Wrba T; Koppensteiner R; Schernthaner GH
    Diab Vasc Dis Res; 2020; 17(2):1479164120914845. PubMed ID: 32308023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiorenal and other diabetes related outcomes with SGLT-2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes: nationwide observational study.
    Lugner M; Sattar N; Miftaraj M; Ekelund J; Franzén S; Svensson AM; Eliasson B
    Cardiovasc Diabetol; 2021 Mar; 20(1):67. PubMed ID: 33752680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BMI variability and cardiovascular outcomes within clinical trial and real-world environments in type 2 diabetes: an IMI2 SOPHIA study.
    Massey RJ; Chen Y; Panova-Noeva M; Mattheus M; Siddiqui MK; Schloot NC; Ceriello A; Pearson ER; Dawed AY
    Cardiovasc Diabetol; 2024 Jul; 23(1):256. PubMed ID: 39014446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improvement of glycemic control and reduction of major cardiovascular events in 18 cardiovascular outcome trials: an updated meta-regression.
    Maiorino MI; Longo M; Scappaticcio L; Bellastella G; Chiodini P; Esposito K; Giugliano D
    Cardiovasc Diabetol; 2021 Oct; 20(1):210. PubMed ID: 34663316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of diabetes duration on the relationship between glycaemic control and risk of death in older adults with type 2 diabetes.
    Ghouse J; Isaksen JL; Skov MW; Lind B; Svendsen JH; Kanters JK; Olesen MS; Holst AG; Nielsen JB
    Diabetes Obes Metab; 2020 Feb; 22(2):231-242. PubMed ID: 31596048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative predictive ability of visit-to-visit HbA1c variability measures for microvascular disease risk in type 2 diabetes.
    Yang CY; Su PF; Hung JY; Ou HT; Kuo S
    Cardiovasc Diabetol; 2020 Jul; 19(1):105. PubMed ID: 32631323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Considerably decreased risk of cardiovascular disease with combined reductions in HbA1c, blood pressure and blood lipids in type 2 diabetes: Report from the Swedish National Diabetes Register.
    Eeg-Olofsson K; Zethelius B; Gudbjörnsdottir S; Eliasson B; Svensson AM; Cederholm J
    Diab Vasc Dis Res; 2016 Jul; 13(4):268-77. PubMed ID: 27190080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glycemic control and clinical outcomes in diabetic patients with heart failure and reduced ejection fraction: insight from ventricular remodeling using cardiac MRI.
    Shi K; Zhang G; Fu H; Li XM; Gao Y; Shi R; Xu HY; Li Y; Guo YK; Yang ZG
    Cardiovasc Diabetol; 2024 Apr; 23(1):148. PubMed ID: 38685007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploring potential mediators of the cardiovascular benefit of dulaglutide in type 2 diabetes patients in REWIND.
    Konig M; Riddle MC; Colhoun HM; Branch KR; Atisso CM; Lakshmanan MC; Mody R; Raha S; Gerstein HC
    Cardiovasc Diabetol; 2021 Sep; 20(1):194. PubMed ID: 34563178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of Intensive Glycemic Control on Clinical Outcomes Among Patients With Type 2 Diabetes With Different Levels of Cardiovascular Risk and Hemoglobin A
    Tian J; Ohkuma T; Cooper M; Harrap S; Mancia G; Poulter N; Wang JG; Zoungas S; Woodward M; Chalmers J
    Diabetes Care; 2020 Jun; 43(6):1293-1299. PubMed ID: 32193249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.